-+ 0.00%
-+ 0.00%
-+ 0.00%

CERo Therapeutics Doses Seventh Patient in Phase 1 CER-1236 Trial

PUBT·11/03/2026 13:16:06
Listen to the news
CERo Therapeutics Doses Seventh Patient in Phase 1 CER-1236 Trial
  • CERo Therapeutics announced Nov. 3, 2026, it dosed the seventh patient in its Phase 1 CER-1236 blood cancer trial.
  • Previously reported findings showed no dose-limiting toxicities in the second cohort's first three patients; infused cells expanded following treatment.
  • The study has expanded beyond acute myeloid leukemia to include myelodysplastic syndromes and myelofibrosis.
  • Safety monitoring remains ongoing; the company plans to report further progress.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cero Therapeutics Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611030815PRIMZONEFULLFEED9868665) on November 03, 2026, and is solely responsible for the information contained therein.